Derrick Gingery
[4] Leili Gao et.al, Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial, Nature Medicine | Volume 29 | June 2023 | 1500–1510. [5] 《减肥神药GLP-1的下一个百亿市场——NASH》,见智研究Pr...
Some were concurrently receiving insulin or some of the other newer diabetes drugs like SGLT2 inhibitors, so that can certainly confound the degree of weight loss. In patients with breast cancer receiving a GLP-1 agonist, do you feel there’s a potential for prescribing this consistently as AE...
This activates GLP-1 receptors in your body, leading to an increase in the production of insulin, which helps move glucose into your cells, where it’s used for energy, Dr. Shah says. But GLP-1 receptor agonists do more than just help shuttle glucose around your body. “These medications...
[4] Leili Gao et.al, Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial, Nature Medicine | Volume 29 | June 2023 | 1500–1510. [5] 《减肥神药GLP-1的下一个百亿市场——NASH》,见智研究Pr...
[4] Leili Gao et.al, Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial, Nature Medicine | Volume 29 | June 2023 | 1500–1510. [5] 《减肥神药GLP-1的下一个百亿市场——NASH》,见智研究Pr...
1RAs [1] and SGLT2is [2]. Beneficial effects are also observed in patients with fatty liver disease [3]. GLP-1RAs act on pancreatic β-cells, augmenting insulin secretion. These drugs also suppress appetite and are beneficial for long term weight management [4]. SGLT2is, on the other ...
diabetes management; once-weekly insulin; GLP-1/GIP receptor agonists; HbA1c reduction; treatment tolerability1. Introduction Diabetes mellitus (DM) imposes a substantial global burden, contributing significantly to morbidity and mortality rates, particularly due to associated complications such as ...